(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
-0.45% ¥ 1 535.00
Live Chart Being Loaded With Signals
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...
Stats | |
---|---|
Volumen de hoy | 196 700 |
Volumen promedio | 305 953 |
Capitalización de mercado | 63.91B |
EPS | ¥0 ( 2024-02-01 ) |
Próxima fecha de ganancias | ( ¥12.99 ) 2024-05-08 |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 11.61 |
ATR14 | ¥0.938 (0.06%) |
Volumen Correlación
Shin Nippon Biomedical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Shin Nippon Biomedical Correlación - Moneda/Commodity
Shin Nippon Biomedical Finanzas
Annual | 2022 |
Ingresos: | ¥25.09B |
Beneficio Bruto: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Ingresos: | ¥25.09B |
Beneficio Bruto: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Ingresos: | ¥17.75B |
Beneficio Bruto: | ¥9.69B (54.58 %) |
EPS: | ¥171.20 |
FY | 2021 |
Ingresos: | ¥15.11B |
Beneficio Bruto: | ¥7.55B (49.99 %) |
EPS: | ¥87.95 |
Financial Reports:
No articles found.
Shin Nippon Biomedical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥0.500 | 2004-03-26 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | ¥99.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.65 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.81 | |
Div. Directional Score | 7.68 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8140.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7494.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6718.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6062.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
4743.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3984.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
3193.T | Ex Dividend Junior | 2024-01-30 | Annually | 0 | 0.00% | |
2183.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
9058.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7944.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.0771 | 1.200 | 7.43 | 8.92 | [0 - 0.3] |
returnOnEquityTTM | 0.192 | 1.500 | 8.98 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.496 | 0.800 | 7.52 | 6.02 | [1 - 3] |
quickRatioTTM | 0.835 | 0.800 | 9.80 | 7.84 | [0.8 - 2.5] |
cashRatioTTM | 0.571 | 1.500 | 7.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.374 | -1.500 | 3.77 | -5.65 | [0 - 0.6] |
interestCoverageTTM | 30.41 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.884 | -1.500 | 6.46 | -9.69 | [0 - 2.5] |
grossProfitMarginTTM | 0.522 | 1.000 | 4.63 | 4.63 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.150 | 1.000 | 9.01 | 9.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.134 | 1.000 | -0.368 | -0.368 | [0.2 - 2] |
assetTurnoverTTM | 0.374 | 0.800 | -0.839 | -0.671 | [0.5 - 2] |
Total Score | 10.55 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.61 | 1.000 | 8.93 | 0 | [1 - 100] |
returnOnEquityTTM | 0.192 | 2.50 | 9.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.26 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.775 | 1.500 | -8.50 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.134 | 1.000 | 9.16 | 0 | [0.1 - 0.5] |
Total Score | 4.81 |
Shin Nippon Biomedical
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico